American CryoStem Corporation announced a major transaction in mainland China with Health Innovative Technology of Hong Kong (HIT). After more than two years as CRYO's licensee in Hong Kong, HIT has licensed the patent rights to distribute the Company's ATGRAFT and CELLECT platform in mainland China. To facilitate the expansion, CRYO has extended the licensing and distribution agreement with HIT to establish two additional entities; Health Innovative Technology Shenzhen and Baoxin Asia Pacific Biotechnology Co, LTD, which will develop, own and operate multiple laboratory/treatment/training facilities in China. CRYO has received an upfront fee of $300,000 and a 5-year minimum annual guarantee of $500,000 per year. Additionally, as part of the transaction CRYO will obtain a minority equity stake in Baoxin, (China) and up to a 20% equity ownership interest in the Regenerative Medicine center in Hong Kong.